Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Nonstent-based local drug delivery during percutaneous intervention offers potential for
sustained antirestenotic efficacy without the limitations of permanent vascular implants …

Objectives The aim of this randomized controlled trial was to investigate a novel sirolimus-
coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB) …

Objectives The aim of this randomized controlled trial was to investigate a novel sirolimus-
coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB) …

Background Calcific atherosclerosis is a major challenge to intraluminal drug delivery in
peripheral artery disease (PAD). Objectives We evaluated the effects of orbital atherectomy …

The most common treatment for obstructive coronary artery disease (CAD) is the
implantation of a permanent drug-eluting stent (DES). Not only has this permanency been …

The drug-coated balloon (DCB) is an emerging percutaneous coronary intervention (PCI)
device that delivers drugs to diseased vessels to decrease the rate of vascular stenosis …

Background—Limus-eluting stents are dominating coronary interventions, although
paclitaxel is the only drug on balloon catheters with proven inhibition of restenosis …

Drug-coated balloons (DCBs) are used commonly for delivering drug into diseased arteries.
When applied on the inner surface of an artery, drug is transported from the balloon into the …

Drug‐coated balloon (DCB) percutaneous interventional therapy allows for durable
reopening of the narrowed lumen via physical tissue expansion and local anti‐restenosis …